Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

Abroad (travel likely)RecruitingPHASE2

Conditions

Breast Cancer Stage I · Breast Cancer Stage II · Breast Cancer Stage III · Carcinoma, Breast

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

George Washington-Medical Faculty Associates, Washington D.C., District of Columbia, United States
Contact: Study coordinator (Richard Lush, PhD) · rmlush3@gwu.edu · 202-994-0329

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

Breast · Metastatic · Triple Negative

Abroad (travel likely)RecruitingPHASE1, PHASE2

Los Angeles, United States · Los Angeles, United States

Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

Invasive Ductal Breast Carcinoma · Invasive Ductal Carcinoma, Breast · DCIS

Abroad (travel likely)RecruitingPHASE2

Norwalk, United States · Miami, United States

Capecitabine in ER+/HER2-negative Breast Cancer

ER-positive, HER2-negative Breast Cancer · Breast Cancer Stage I · Breast Cancer Stage II

Abroad (travel likely)RecruitingPHASE2

Toronto, Canada

TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC

Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Brasília, Brazil · Curitiba, Brazil